{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:57:36Z","timestamp":1771009056741,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.leukres.2008.04.026","type":"journal-article","created":{"date-parts":[[2008,6,21]],"date-time":"2008-06-21T08:21:20Z","timestamp":1214036480000},"page":"1830-1836","source":"Crossref","is-referenced-by-count":15,"title":["Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed\/refractory AML"],"prefix":"10.1016","volume":"32","author":[{"given":"Alison R.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jainulabdeen","family":"Ifthikharuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Mulford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.leukres.2008.04.026_bib1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission","volume":"339","author":"Cassileth","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.leukres.2008.04.026_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","article-title":"Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia","volume":"79","author":"Wiernik","year":"1992","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2008.04.026_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2008.04.026_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428190009053545","article-title":"Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"39","author":"Robak","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2008.04.026_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/1042819021000054670","article-title":"In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential","volume":"44","author":"Chow","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2008.04.026_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","article-title":"A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukaemia\u2014a report of the Polish Adult Leukemia Group (PALG)","volume":"71","author":"Wrzesien-Kus","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.04.026_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cncr.22471","article-title":"Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-c and imatinib","volume":"109","author":"Heidel","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2008.04.026_bib8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.V92.2.596","article-title":"The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL)","volume":"92","author":"Bene","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.026_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1998.01072.x","article-title":"Systemic mastocytosis associated with acute myeloid leukemia: report of two cases and detection of the c-kit mutation Asp-816 to Val","volume":"103","author":"Sperr","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.04.026_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia","volume":"105","author":"Gary","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.04.026_bib11","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood.V90.11.4539","article-title":"Expression of constitutively activated human c-kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity","volume":"90","author":"Ferrao","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2008.04.026_bib12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2008.04.026_bib13","first-page":"561a","article-title":"A phase II pilot study of Gleevec\/Glivec (Imatinib Mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML)","volume":"100","author":"Fischer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2008.04.026_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00280-003-0668-y","article-title":"Avramis VI: determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and\/or STI571 (imatinib mesylate Gleevec) with cytotoxic drugs against human leukemia cell lines","volume":"52","author":"Avramis","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2008.04.026_bib15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Risto","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.leukres.2008.04.026_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply \u2018Cardiotoxicity of the cancer thereapeutic agent imatinib mesylate\u2019","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2008.04.026_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404188","article-title":"Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)","volume":"20","author":"Boissel","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.04.026_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","article-title":"KIT-D816 mutations in AML-ETO-positive AML are associated with impaired event-free and overall survival","volume":"107","author":"Schnittger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.026_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T14:10:59Z","timestamp":1588774259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608002397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0145212608002397"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.04.026","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}